Notifications
2 minutes, 56 seconds
-15 Views 0 Comments 0 Likes 0 Reviews
Drug supply chains are facing increasing risks from geopolitical and environmental disorders. CDMO plays an important role in ensuring medical supply stability by using flexible strategies. As the industry develops, small-molecule CDMOs should embrace innovation and agility to balance supply and demand, promote progress and improve the patient results in a dynamic landscape.
Focus on large-molecule therapeutics is often faced with challenges with small-molecule medications. These medicines are affected by financing barriers, disruption in the supply chain, and increasing demand. The small-molecule market is expected to expand significantly in the coming years, which is inspired by the discovery of patient-focused medicines and progress in innovation in areas such as oncology, cardiology, and neurology.
The drugs are estimated to increase from $57.41 billion to $106 billion by 2031 in 2023. This contract development and manufacturing organization (CDMO) highlights a developed landscape with specialization in small molecules. By implementing effective strategies, these organizations can continue to support the production of essential medicines that improve patients health.
Since 2000, a series of global crises have highlighted the weaknesses of the drug supply chains. Events such as the financial crisis in 2008, the COVID-19 epidemic, and the ongoing war in Ukraine have created the availability of important materials, an increase in production costs, and regulatory challenges.
For example, clinical trials in Europe have been heavily influenced by the Ukraine conflict. In the end of 2020 and early 2022, 255 tests were either started or completed in Ukraine. From mid-2022 to mid-2023, as a result, the number fell to 33, which represented a decrease of 87%. This deficiency reflects the widespread effect of regional instability on global drug operations.
The United States is facing a unique reduction in essential medicines with over 250 medications in limited supply. This includes small molecular agents such as penicillin, Adderall, and methotrexate, which have been affected since October 2022. The demand for targeted treatment of chronic conditions, especially associated with an aging population, is increasing. By this there has been a significant decline in resources dedicated to small molecular drug development.
Read more: https://www.pharmafocusamerica.com/biopharma/strengthening-drug-supply-chains
SupplyChain CDMO strategies pharma focus america CDMO Pharma cdmo
